Klaria Pharma Holding
Research Klaria Pharma Holding (KLAR.ST) on Bullrun: market cap SEK 147.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKLAR.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 147.34M
- Financial periodQ1 2026
- RevenueSEK 101.00K
- Net income-SEK 8.66M
- Free cash flow-SEK 82.00K
Valuation Snapshot
latest market cap is SEK 147.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 9.03M | -SEK 38.89M | -SEK 35.04M | n/a | -0.22 | SEK 342.00K | SEK 25.00M | -SEK 12.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 147.34M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Klaria Pharma Holding
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Klaria Pharma Holding's market cap?
Klaria Pharma Holding's market capitalization is SEK 147.34M.
What does Klaria Pharma Holding do?
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids.